4DMT shoots for a $75M IPO, its second attempt to go public with its gene therapy vector programs
Just a few months after withdrawing its IPO filing, 4D Molecular Therapeutics is seeking to go public once again.
The Emeryville, CA-based company submitted a new S-1 on Tuesday, detailing plans for a $75 million raise as it aims for the second time to hit the Nasdaq. 4DMT had previously sought a $100 million IPO back in September 2019, but withdrew the filing in July of this year after completing a $75 million Series C in June.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.